Friday, November 15, 2013 – 10:00am Health Subcommittee – 2322 Rayburn House Office Building, Washington DC
Many members of Congress brought up concerns about how FDASIA implementation is affecting Rare Disease Drug Development. Dr. Woodcock, FDA’s Director of the Center for Drug Evaluation & Research (CDER) explained how the rare diseases programs at the FDA have been hindered due to Sequestration.
Janet Woodcock, M.D.
- Center for Drug Evaluation and Research
- Food and Drug Administration
- Witness Testimony (Truth in Testimony and CV)
Jeffrey E. Shuren, M.D., J.D.
– See more at: http://energycommerce.house.gov/hearing/reviewing-fda%E2%80%99s-implementation-fdasia#video